216 related articles for article (PubMed ID: 38706889)
1. CAR T-cell therapy and the onco-nephrologist.
Salvino MA; Mussetti A; Peña M; Paviglianiti A; Carreira AS; Rizky D; Sureda A
Front Nephrol; 2024; 4():1378250. PubMed ID: 38706889
[TBL] [Abstract][Full Text] [Related]
2. Pediatric onco-nephrology: time to spread the word : Part I: early kidney involvement in children with malignancy.
Nada A; Jetton JG
Pediatr Nephrol; 2021 Aug; 36(8):2227-2255. PubMed ID: 33245421
[TBL] [Abstract][Full Text] [Related]
3. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
4. The Progress and Prospects of Immune Cell Therapy for the Treatment of Cancer.
Han J; Zhang B; Zheng S; Jiang Y; Zhang X; Mao K
Cell Transplant; 2024; 33():9636897241231892. PubMed ID: 38433349
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy.
Johnson GA; Locke FL
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1189-1199. PubMed ID: 37580193
[TBL] [Abstract][Full Text] [Related]
6. Toxicity of Chimeric Antigen Receptor T Cells and its Management.
Wudhikarn K; Soh SY; Huang H; Perales MA
Blood Cell Ther; 2021 Oct; 4(Spec Edition):S1-S7. PubMed ID: 36713468
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances.
Canichella M; Molica M; Mazzone C; de Fabritiis P
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201469
[TBL] [Abstract][Full Text] [Related]
8. Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.
Yoo JW
Blood Res; 2023 Apr; 58(S1):S20-S28. PubMed ID: 36891576
[TBL] [Abstract][Full Text] [Related]
9. Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology.
Attieh RM; Nunez B; Copeland-Halperin RS; Jhaveri KD
Cardiorenal Med; 2024 Apr; ():. PubMed ID: 38684145
[TBL] [Abstract][Full Text] [Related]
10. Onco-nephrology: current concepts and future perspectives.
Kitai Y; Matsubara T; Yanagita M
Jpn J Clin Oncol; 2015 Jul; 45(7):617-28. PubMed ID: 25784734
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
12. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
[TBL] [Abstract][Full Text] [Related]
13. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
14. Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group.
Nezvalova-Henriksen K; Langebrake C; Bauters T; Moreno-Martinez ME; Ahnfelt E; Ekelund H; Domingos V; Pires V; Bonnin A; Bojanić I; Cabrerizo Y; Terwel S; Tam A
Bone Marrow Transplant; 2023 Oct; 58(10):1069-1074. PubMed ID: 37528237
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease and chimeric antigen receptor cellular therapy.
Rao A; Stewart A; Eljalby M; Ramakrishnan P; Anderson LD; Awan FT; Chandra A; Vallabhaneni S; Zhang K; Zaha VG
Front Cardiovasc Med; 2022; 9():932347. PubMed ID: 36211558
[TBL] [Abstract][Full Text] [Related]
16. Onco-Nephrology: Cancer, chemotherapy and kidney.
de Francisco ALM; Macía M; Alonso F; García P; Gutierrez E; Quintana LF; Quiroga B; Torregrosa I
Nefrologia (Engl Ed); 2019; 39(5):473-481. PubMed ID: 30929891
[TBL] [Abstract][Full Text] [Related]
17. Melatonin as an immunomodulator in CD19-targeting CAR-T cell therapy: managing cytokine release syndrome.
Zheng N; Long Y; Bai Z; Li J; Wang H; Song DD; Liu HL; Shi JH; Zhao S
J Transl Med; 2024 Jan; 22(1):58. PubMed ID: 38221609
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.
Polgárová K; Otáhal P; Šálek C; Pytlík R
Front Oncol; 2022; 12():876758. PubMed ID: 35600381
[TBL] [Abstract][Full Text] [Related]
19. Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant.
Nada A; Jetton JG
Pediatr Nephrol; 2022 Jun; 37(6):1285-1300. PubMed ID: 34490519
[TBL] [Abstract][Full Text] [Related]
20. Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.
Jhaveri KD; Rosner MH
Clin J Am Soc Nephrol; 2018 May; 13(5):796-798. PubMed ID: 29523675
[No Abstract] [Full Text] [Related]
[Next] [New Search]
